Hypointense Hepatic Lesions Depicted on Gadobenate Dimeglumine-Enhanced Three-Hour Delayed Hepatobiliary-Phase MR Imaging: Differentiation between Benignancy and Malignancy by Hwang, Hye Sun et al.
294 Korean J Radiol 10(3), June 2009
Hypointense Hepatic Lesions Depicted on
Gadobenate Dimeglumine-Enhanced
Three-Hour Delayed Hepatobiliary-Phase
MR Imaging: Differentiation between
Benignancy and Malignancy
Gadobenate dimeglumine-enhanced magnetic resonance (MR) imaging simul-
taneously provides both morphological and functional information by the acquisi-
tion of dynamic and hepatobiliary-phase imaging. Focal lesions with no function-
ing hepatocytes, where hepatobiliary metabolism is blocked or inhibited, are gen-
erally unable to uptake and excrete gadobenate dimeglumine into the bile. Such
lesions are typically malignant and usually appear hypointense as compared to
the normal liver parenchyma as seen on hepatobiliary-phase imaging. However,
various benign hepatic lesions may also be hypointense due to (a) the presence
of no functioning hepatocytes, (b) damage to the functioning hepatocytes or (c)
impairment of biliary function as depicted on hepatobiliary-phase imaging. All of
these imaging features may result in recognition of the benign hepatic lesions as
hepatic malignancies. As depicted on three-hour delayed hepatobiliary-phase
imaging, peripheral iso/hyperintensity due to fibrotic tissue compared to the
hypointense center with a fuzzy margin may be a clue for the presence of a
benign hepatic lesion. In contrast, peripheral hypointensity due to rich tumoral
cellularity compared to the center with a clear margin may favor an indication of
the presence of a malignant hepatic lesion.
adobenate dimeglumine (gadolinium-benzyloxypropionictetraacetate
[BOPTA], MultiHance; Bracco Imaging, Milan, Italy) can be used not
only as a non-specific extracellular contrast agent for dynamic imaging of
the liver, but also as a liver-specific agent for the acquisition of hepatobiliary-phase
images (1-4). Therefore, gadobenate dimeglumine-enhanced magnetic resonance (MR)
imaging simultaneously provides both morphological and functional information.
In general, lesions that contain functioning hepatocytes where hepatobiliary
metabolism is mostly unaltered may be expected to uptake gadobenate dimeglumine
in the same manner as normal hepatocytes and the lesions may be expected to
excrete the compound into the bile. Such lesions are typically benign and usually
appear isointense or hyperintense as compared to the normal liver parenchyma as
depicted on gadobenate dimeglumine-enhanced hepatobiliary-phase MR imaging. In
contrast, lesions that do not contain functioning hepatocytes where hepatobiliary
metabolism is blocked or inhibited are generally not able to uptake and excrete
gadobenate dimeglumine into the bile. Such lesions are typically malignant and
usually appear hypointense as compared to the normal liver parenchyma as depicted
on gadobenate dimeglumine-enhanced hepatobiliary-phase MR imaging (4-11).
However, some benign lesions may be hypointense as seen on gadobenate dimeglu-
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Gmine-enhanced hepatobiliary-phase MR imaging and may
be mistaken for hepatic malignancies, resulting in
unnecessary performance of an interventional procedure
such as a biopsy or surgery (4-13).
In this pictorial essay, we describe the mechanism of
enhancement of gadobenate dimeglumine in the liver as
seen on hepatobiliary-phase MR imaging. In addition, we
will present various pathologically proven benign and
malignant hypointense hepatic lesions as depicted on
gadobenate dimeglumine-enhanced three-hour delayed
hepatobiliary-phase MR imaging, with an emphasis on the
differential diagnosis between benignancy and malignancy.
Mechanism of Hepatic Uptake and Biliary Excretion
of Gadobenate Dimeglumine
Gadobenate dimeglumine is a gadolinium-based contrast
agent, which possesses a two-fold greater T1 relaxivity as
compared to conventional gadolinium-based agents in
human plasma, due to a weak and transient interaction
with serum albumin (1, 2). Gadobenate dimeglumine
undergoes elimination from the body through both a renal
(95-97% of the injected dose) and hepatobiliary pathway
(2, 3). Approximately 3-5% of the injected dose is taken
up into the functioning hepatocytes through the action of
organic anion transporting peptide 1 and the compound is
eliminated into the bile by the adenosine triphosphate
(ATP)-dependent canalicular multispecific organic anion
transporter peptide (cMOAT), multidrug resistance-associ-
ated protein 2 (Mrp2) that transports bilirubin (Fig. 1) (14-
18).
Hepatobiliary-Phase MR Imaging of Gadobenate
Dimeglumine 
It is known that as seen on gadopentetate dimeglumine
(Gd-DTPA)-enhanced 1-hour to 4-hour delayed MR
imaging, the area with delayed enhancement corresponds
pathologically to abundant fibrosis, the hypointense rim
corresponds to rich tumoral cellularity and the hypointense
center corresponds to coagulative necrosis (19). The
enhancement of focal hepatic lesions as seen on gadobe-
nate dimeglumine-enhanced hepatobiliary-phase MR
imaging is affected by the internal component of the
lesions such as the sinusoid-like vascular space or fibrosis,
which is similar to the enhancement mechanism of Gd-
DTPA. The enhancement of focal hepatic lesions is also
affected by the retained hepatocyte activity of the lesion,
which is unique as compared with the effect of Gd-DTPA
(6, 19, 20). Appropriate gadobenate dimeglumine-
enhanced hepatobiliary-phase MR imaging can be
performed from 40 minutes after the injection of the
contrast agent and the strong enhancement of normal liver
parenchyma is maintained for a period of 120 minutes or
longer (2, 18). In our institute, hepatobiliary-phase MR
imaging has been obtained three hours after the injection
of gadobenate dimeglumine for the minimization of the
extracellular effects of the contrast agent.
Benign Hypointense Hepatic Lesions
A variety of benign hepatic lesions can appear
hypointense as depicted on gadobenate dimeglumine-
enhanced hepatobiliary-phase MR imaging due to the
following causes. (a) No functioning hepatocytes are
present in the lesion, (b) damage to the functioning hepato-
cytes has occurred due to infection or inflammation and (c)




Cysts (Fig. 2) and hemangiomas (Fig. 3) are the most
common benign lesions in the liver that lack functioning
hepatocytes (5, 6). The differentiation of these lesions from
other malignant hypointense hepatic lesions is possible
with the use of unenhanced and gadobenate dimeglumine-
enhanced dynamic MR imaging.
Mesenchymal Tumors
A variety of mesenchymal tumors of the liver with no
functioning hepatocytes including angiomyolipomas and
solitary fibrous tumors can appear as hypointense as
depicted on gadobenate dimeglumine-enhanced hepatobil-
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Fig. 1. Schematic illustration of proposed sinusoidal and canalic-
ular transport pathway of gadobenate dimeglumine in rat liver.
Approximately 3-5% of injected dose is taken up into functioning
hepatocytes by organic anion transporting polypeptide1 (Oatp1)
and is eliminated into bile by action of adenosine triphosphate
(ATP)-dependent canalicular multispecific organic anion
transporter peptide (cMOAT), multidrug resistance-associated
protein 2 that transports bilirubin.iary-phase MR imaging; the appearance of these lesions
may mimic a malignant tumor. We have experienced a
rare mesenchymal tumor (21, 22), a hypointense solitary
fibrous tumor with a clear margin (Fig. 4) as seen on
gadobenate dimeglumine-enhanced hepatobiliary-phase
MR imaging, which mimicked a malignant tumor.
Miscellaneous
We have experienced a reactive lymphoid hyperplasia
(Fig. 5) in the liver that is a rare benign nodular lesion
characterized by marked proliferation of non-neoplastic,
polyclonal lymphocytes that form follicles with an active
germinal center (23, 24). This nodule appeared
hypointense with a clear margin as seen on gadobenate
dimeglumine-enhanced hepatobiliary-phase MR imaging
and mimicked a malignant tumor.
Damage of Functioning Hepatocytes
Focal Eosinophilic Liver Disease
Focal eosinophilic liver lesions including focal
eosinophilic infiltration, eosinophilic abscess and
granuloma (Fig. 6) are composed of inflammatory cell
infiltration with a large proportion of eosinophils with or
Hwang et al.
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Fig. 2. 63-year-old woman with hepatic
cysts and hepatocellular carcinoma that
were confirmed after hepatic resection.
A. Respiratory-triggered single-shot T2-
weighted MR image shows typical
hyperintense cysts. Small hyperintense
lesion (arrow) is cyst. Enlargement of
lymph node (arrowhead) in right cardio-
phrenic area is noted.
B. Gadobenate dimeglumine-enhanced
three-hour delayed hepatobiliary-phase
MR image shows multiple hypointense
lesions. Small hypointense lesion
(arrow) is cyst. Enlargement of lymph




Fig. 3. 32-year-old woman with hemangioma that was confirmed by typical CT and MR imaging findings.
A. Respiratory-triggered single-shot T2-weighted MR image shows very hyperintense lesion in right liver.
B. Gadobenate dimeglumine-enhanced arterial-phase MR image shows typical peripheral globular enhancement of hemangioma.
C. Transverse three-hour delayed hepatobiliary-phase MR image shows discrete hypointense lesion.without coagulation necrosis (25-27). Imaging findings of
focal eosinophilic liver disease as seen on gadobenate
dimeglumine-enhanced hepatobiliary-phase MR imaging
depend on the degree of inflammation and the destruction
of the liver parenchyma. The peripheral portion of an
eosinophilic focal lesion may show retention of the
contrast agent due to inflammation as compared with the
central necrotic portion, which may result in the depiction
of a fuzzy margin due to peripheral isointensity or
hyperintensity relative to the center (Fig. 6).
Infectious Lesions
With the use of gadobenate dimeglumine-enhanced
hepatobiliary-phase MR imaging, imaging findings of
inflammatory lesions (Fig. 7) such as hepatic abscesses may
vary depending on the difference in the degree of inflam-
mation and destroyed hepatic parenchyma (11, 13). The
presence of peripheral isointensity or hyperintensity of an
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ABC
Fig. 5. 61-year-old woman with reactive lymphoid hyperplasia that was confirmed after hepatic resection in liver. Patient had colon
cancer.
A. Contrast-enhanced CT scan obtained during portal-phase shows discrete hypodense nodule (arrow) that mimicked metastatic nodule
in left liver.
B. Respiratory-triggered single-shot T2-weighted MR image shows hyperintense nodule (arrow).
C. Gadobenate-dimeglumine-enhanced three-hour delayed hepatobiliary-phase MR image shows hypointense nodule with clear margin
(arrow) that mimicked metastatic nodule in left liver.
Fig. 4. 47-year-old woman with solitary fibrous tumor that was confirmed by hepatic resection.
A. Respiratory-triggered single-shot T2-weighted MR image shows heterogeneous hypointense and hyperintense mass with central
hyperintense area.
B, C. Gadobenate dimeglumine-enhanced arterial- (B) and equilibrium-phase (C) MR images show heterogeneous arterial hypervascu-
lar enhancing mass, followed by persistent homogeneous enhancement except for central area.
D. Three-hour delayed hepatobiliary-phase MR image shows discrete hypointense mass with enhancement of central area due to
fibrosis.
ABCDinflammatory lesion may be mainly due to the retention of
the contrast agent in fibrous tissues, from an inflammatory
change due to extensive fibrosis as relative to the
hypointensity (necrosis) of the center, and may suggest
that the lesion is not typically malignant in nature.
Impaired Biliary Function
Hepatic Adenomas
Although a hepatic adenoma (Fig. 8) has functioning
hepatocytes, it lacks bile ducts (7, 8, 28). Therefore, it is
likely that the hepatocellular bilirubin metabolism is
blocked in the adenoma, as confirmed by the absence of
Hwang et al.
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Fig. 6. 68-year-old woman with eosinophilic granuloma that was confirmed after hepatic resection. Patient had history of surgery for
colon cancer two years prior.
A. Contrast-enhanced CT scan obtained during portal-phase shows hypodense nodule (arrow) with peripheral ring-like enhancement in
left liver.
B. Respiratory-triggered single-shot T2-weighted MR image obtained 12 days after CT examination shows hyperintense nodule (arrow).
C. Gadobenate dimeglumine-enhanced three-hour delayed hepatobiliary-phase MR image obtained 12 days after CT examination
shows lesion (arrow) with peripheral isointensity and central hypointensity.
D. Photomicrograph of resected specimen shows inflammatory cell infiltration with fibroblast proliferation (asterisks), which appeared to
be ring enhancement as seen on hepatobiliary-phase MR image. Necrosis (N) corresponds to central hypointensity as seen on the
hepatobiliary-phase MR image. L = normal liver (Hematoxylin & Eosin staining, ×100).
ABCD
Fig. 7. 45-year-old man with inflammatory mass that was confirmed after percutaneous biopsy in normal liver.
A, B. Contrast-enhanced CT scans obtained during arterial- (A) and equilibrium-phase (B) show discrete hypodense mass with periph-
eral rim-like enhancement in right liver that mimicked cholangiocarcinoma.
C. Respiratory-triggered single-shot T2-weighted MR image obtained three weeks after CT examination shows hyperintense mass.
D. Gadobenate dimeglumine-enhanced three-hour delayed hepatobiliary-phase MR image obtained three weeks after CT examination
shows mass (arrow) with peripheral isointensity compared to hypointense center. This lesion showed decrease in size nine months after
initial CT examination.
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Fig. 8. 73-year-old man with hepatic adenoma that was confirmed after hepatic resection.
A, B. Contrast-enhanced CT scans obtained during arterial- (A) and equilibrium-phase (B) show
mass with peripheral hyperenhancement, followed by washout with peripheral rim-like enhancement
and central hypodensity due to hemorrhage.
C, D. T1-weighted (C) and respiratory-triggered single-shot T2-weighted (D) MR images show mass
with slight hypointensity and hyperintensity, respectively, which may be differential characterization
features from malignant tumor such as advanced hepatocellular carcinoma. Central hemorrhage is
noted.
E. Gadobenate dimeglumine-enhanced three-hour delayed hepatobiliary-phase MR image shows
discrete heterogeneous hypointense mass.
E
ABC
Fig. 9. 44-year-old woman with low-grade dysplastic nodule that was confirmed after percutaneous biopsy in normal liver. Patient did not
have viral infection.
A. Contrast-enhanced CT scan obtained during equilibrium-phase shows small hypodense nodule (arrow) with arterial hypovascularity
(data not shown) in left liver. Two similar hypodense nodules (arrowheads) are noted in left liver.
B. Respiratory-triggered single-shot T2-weighted MR image shows hypointense nodule (arrow).
C. Gadobenate dimeglumine-enhanced three-hour delayed hepatobiliary-phase MR image shows discrete hypointense nodule (arrow).
This nodule and another two nodules in left liver showed no change in size 16 months after initial CT examination.bile in a resected adenoma (28), which results in the
absence of uptake and transport of gadobenate dimeglu-
mine. As seen on gadobenate dimeglumine-enhanced
hepatobiliary-phase MR imaging, an adenoma appears as a
hypointense lesion. Although not always helpful, for the
successful differential diagnosis of hepatic adenomas from
other malignant hypointense hepatic lesions, especially
hepatocellular carcinomas, the use of unenhanced and
gadobenate dimeglumine-enhanced dynamic MR imaging
may be complementary.
Dysplastic Nodules
Dysplastic nodules usually appear isointense as seen on
gadobenate dimeglumine-enhanced hepatobiliary-phase
MR imaging (9, 10). The biliary function of a low-grade
dysplastic nodule is usually preserved and bile ducts are
present in portal areas. In a high-grade dysplastic nodule,
the biliary function may only be partially impaired, in
which portal triads may be focally absent in the nodule and
thus bile ducts may be missing (4). Although confirmation
of the presence of the tumor after performing a needle
Hwang et al.
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Fig. 10. 45-year-old man with hepatocellular carcinoma with central scar that was confirmed after hepatic resection.
A. Respiratory-triggered single-shot T2-weighted MR image shows hyperintense mass in right liver. Central scar is very bright
(arrowhead).
B, C. Gadobenate dimeglumine-enhanced MR images obtained during arterial- (B) and equilibrium-phase (C) show typical enhancement
(hypervascular with washout pattern) of hepatocellular carcinoma with delayed central hyperenhancement due to presence of fibrous
scar (arrowheads).
D. Three-hour delayed hepatobiliary phase MR image shows discrete homogeneous hypointense mass.
ABCD
Fig. 11. 61-year-old woman with cholangiocarcinoma that was confirmed after percutaneous biopsy.
A, B. Contrast-enhanced CT scans obtained during arterial- (A) and equilibrium- (B) show irregular and peripheral enhancing mass,
followed by progressive heterogeneous central enhancement seen in liver.
C. Respiratory-triggered single-shot T2-weighted MR image shows peripheral hyperintense mass with central hypointensity due to
fibrosis.
D. Gadobenate dimeglumine-enhanced three-hour delayed hepatobiliary-phase MR image shows mass with peripheral hypointensity
compared to center.
ABCDbiopsy is not always sufficient to eliminate the need for a
histological examination of the entire tumor after resection
(Fig. 9), uptake and transport of gadobenate dimeglumine
may be impaired in a dysplastic nodule.
Malignant Hypointense Hepatic Lesions
Malignant lesions such as advanced hepatocellular
carcinomas (Fig. 10), cholangiocarcinomas (Fig. 11) and
metastases (Fig. 12) do not contain functioning hepatocytes
and thus cannot retain gadobenate dimeglumine. These
lesions appear hypointense as seen on gadobenate
dimeglumine-enhanced hepatobiliary-phase MR imaging
(4-6, 9, 30).
Malignant hepatic lesions tend to outgrow their blood
supply, producing central necrosis, hemorrhage and
fibrosis, which results in the depiction of various imaging
patterns on gadobenate dimeglumine-enhanced hepatobil-
iary-phase MR imaging. A target appearance that is
defined as peripheral hypointensity relative to the center
(6, 20) may appear in a malignant mass with abundant
fibrosis such as a cholangiocarcinoma and a metastasis. The
pathological features may explain the target appearance,
where the majority of stromal fibrosis is in the center of
the lesions, resulting in the retention of gadobenate
dimeglumine in the center. More abundant tumoral
cellularity is observed in the periphery of the lesion, result-
ing in rim-like hypointensity to the center, which may be
similar to the enhancement mechanism of the target
appearance by Gd-DTPA (29, 30). The target appearance
appears to be more conspicuous on Gd-DTPA-enhanced
hepatobiliary-phase images than Gd-DTPA-enhanced
delayed images due to the marked and prolonged enhance-
ment of the normal liver parenchyma as seen on gadobe-
nate dimeglumine-enhanced hepatobiliary-phase images.
In conclusion, gadobenate dimeglumine has a property of
being a unique liver-specific contrast agent in addition to a
property of being an extracellular contrast agent, which
results in the marked and prolonged enhancement of the
normal liver parenchyma up to three hours after the
administration of the contrast agent with intralesional
enhancement. Based on these features, three-hour delayed
hepatobiliary-phase MR imaging may be helpful in the
characterization of focal liver lesions. Both benign and
malignant hepatic lesions may appear hypointense as seen
on gadobenate dimeglumine-enhanced hepatobiliary-phase
MR imaging. Benign hypointense hepatic lesions as seen on
hepatobiliary-phase imaging alone may be mistaken for
hepatic malignancies, resulting in the performance of an
unnecessary biopsy or surgery. As seen on three-hour
delayed hepatobiliary-phase imaging, peripheral
iso/hyperintensity due to fibrotic tissue compared to the
hypointense center with a fuzzy margin may be a clue of
the presence of a benign hepatic lesion. In contrast, periph-
eral hypointensity due to rich tumoral cellularity compared
to the center with a clear margin may favor the presence of
a malignant hepatic lesion.
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Fig. 12. 68-year-old man with hepatic metastasis that was confirmed after hepatic resection. Patient had sigmoid colon cancer.
A. Contrast-enhanced CT scan obtained during portal-phase shows mass with peripheral rim-like enhancement in right liver.
B. Respiratory-triggered single-shot T2-weighted MR image shows hyperintense mass.
C. Gadobenate dimeglumine-enhanced three-hour delayed hepatobiliary-phase MR image shows mass with peripheral hypointensity
compared to center.
D. Photomicrograph of resected specimen shows rich tumoral cellularity (asterisks) in periphery of metastatic nodule, which is seen with
peripheral hypointensity compared to center that consisted of fibrosis and necrosis (F & N) as depicted on hepatobiliary-phase MR
image. L = normal liver (Hematoxylin & Eosin staining, ×50).
ABCDHwang et al.
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